Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Allergan, Inc. v. Watson Pharmaceuticals, Inc.
Case Number:
13-1249
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
September 15, 2014
Fed. Circ. Won't Consider Sales Ban On Generic Latisse
The Federal Circuit on Friday refused to reconsider its decision to lift an injunction on generic versions of Allergan Inc.'s eyelash growth stimulant Latisse after previously ruling that two patents covering the drug were obvious in light of prior art.
-
June 10, 2014
Fed. Circ. Ends Sales Ban On Generic Latisse
The Federal Circuit on Tuesday lifted an injunction on generic versions of Allergan Inc.'s eyelash growth stimulant Latisse planned by Apotex Inc. and others, ruling that two patents covering the drug are invalid.